Related Experiment Videos
Opportunities and challenges in targeting HIV entry.
Mark J Biscone1, Theodore C Pierson, Robert W Doms
1Department of Microbiology, 225 Johnson Pavilion, University of Pennsylvania, Philadelphia, PA 19104, USA.
Current Opinion in Pharmacology
|September 27, 2002
Summary
Understanding how Human Immunodeficiency Virus type 1 (HIV-1) enters cells aids in developing new drug targets. HIV-1 entry inhibitors show promise for improving treatment options, especially for drug-resistant infections.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- HIV-1 entry mechanisms are crucial for understanding viral tropism and pathogenesis.
- Identifying cellular entry pathways provides targets for novel therapeutic interventions.
- Current HIV-1 therapies face challenges with drug resistance and treatment failure.
Purpose of the Study:
- To characterize the mechanisms of HIV-1 cellular entry.
- To explore the development and potential of HIV-1 entry inhibitors.
- To assess the therapeutic implications of entry inhibitors for HIV-1 treatment.
Main Methods:
- Investigating the interaction between the viral envelope protein and host cell receptors.
- Developing antagonists that block viral entry.
- Designing peptides to inhibit intermediate fusion processes.
Main Results:
- Characterization of HIV-1 entry mechanisms has advanced understanding of tropism and pathogenesis.
- Several classes of HIV-1 entry inhibitors have been developed.
- In vitro studies show promise for entry inhibitors, with some in clinical trials.
Conclusions:
- HIV-1 entry inhibitors represent a promising therapeutic strategy.
- These inhibitors can potentially improve treatment options for individuals with drug-resistant or failing therapies.
- Targeting viral entry is a viable approach for rational drug design in HIV-1 treatment.